Glial Cells Improve Parkinson's Disease by Modulating Neuronal Function and Regulating Neuronal Ferroptosis

Overview

Journal Front Cell Dev Biol

Date 2025 Jan 20

PMID 39830208

Authors

Mengzhu Li

Mengxuan Chen

Haiyan Li

Da Gao

Lijun Zhao

Meiling Zhu

Affiliations

Soon will be listed here.

Abstract

The main characteristics of Parkinson's disease (PD) are the loss of dopaminergic (DA) neurons and abnormal aggregation of cytosolic proteins. However, the exact pathogenesis of PD remains unclear, with ferroptosis emerging as one of the key factors driven by iron accumulation and lipid peroxidation. Glial cells, including microglia, astrocytes, and oligodendrocytes, serve as supportive cells in the central nervous system (CNS), but their abnormal activation can lead to DA neuron death and ferroptosis. This paper explores the interactions between glial cells and DA neurons, reviews the changes in glial cells during the pathological process of PD, and reports on how glial cells regulate ferroptosis in PD through iron homeostasis and lipid peroxidation. This opens up a new pathway for basic research and therapeutic strategies in Parkinson's disease.

References

Quintana C, Gutierrez L . Could a dysfunction of ferritin be a determinant factor in the aetiology of some neurodegenerative diseases?. Biochim Biophys Acta. 2010; 1800(8):770-82. DOI: 10.1016/j.bbagen.2010.04.012. View

Kasindi A, Fuchs D, Koronyo Y, Rentsendorj A, Black K, Koronyo-Hamaoui M . Glatiramer Acetate Immunomodulation: Evidence of Neuroprotection and Cognitive Preservation. Cells. 2022; 11(9). PMC: 9099707. DOI: 10.3390/cells11091578. View

Chorna N, Santiago-Perez L, Erb L, Seye C, Neary J, Sun G . P2Y receptors activate neuroprotective mechanisms in astrocytic cells. J Neurochem. 2004; 91(1):119-32. DOI: 10.1111/j.1471-4159.2004.02699.x. View

Eyo U, Peng J, Swiatkowski P, Mukherjee A, Bispo A, Wu L . Neuronal hyperactivity recruits microglial processes via neuronal NMDA receptors and microglial P2Y12 receptors after status epilepticus. J Neurosci. 2014; 34(32):10528-40. PMC: 4200107. DOI: 10.1523/JNEUROSCI.0416-14.2014. View

Wang L, Liu Y, Yan S, Du T, Fu X, Gong X . Disease Progression-Dependent Expression of CD200R1 and CX3CR1 in Mouse Models of Parkinson's Disease. Aging Dis. 2020; 11(2):254-268. PMC: 7069458. DOI: 10.14336/AD.2019.0615. View

Sarkar S, Malovic E, Harishchandra D, Ghaisas S, Panicker N, Charli A . Mitochondrial impairment in microglia amplifies NLRP3 inflammasome proinflammatory signaling in cell culture and animal models of Parkinson's disease. NPJ Parkinsons Dis. 2017; 3:30. PMC: 5645400. DOI: 10.1038/s41531-017-0032-2. View

Rocha S, Saraiva T, Cristovao A, Ferreira R, Santos T, Esteves M . Histamine induces microglia activation and dopaminergic neuronal toxicity via H1 receptor activation. J Neuroinflammation. 2016; 13(1):137. PMC: 4893260. DOI: 10.1186/s12974-016-0600-0. View

Khan M, Kempuraj D, Zaheer S, Zaheer A . Glia maturation factor deficiency suppresses 1-methyl-4-phenylpyridinium-induced oxidative stress in astrocytes. J Mol Neurosci. 2014; 53(4):590-9. PMC: 4101074. DOI: 10.1007/s12031-013-0225-z. View

Chen S, Oyarzabal E, Hong J . Critical role of the Mac1/NOX2 pathway in mediating reactive microgliosis-generated chronic neuroinflammation and progressive neurodegeneration. Curr Opin Pharmacol. 2015; 26:54-60. PMC: 4716876. DOI: 10.1016/j.coph.2015.10.001. View

10.

Zhu Y, Wang B, Tao K, Yang H, Wang Y, Zhou T . Iron accumulation and microglia activation contribute to substantia nigra hyperechogenicity in the 6-OHDA-induced rat model of Parkinson's disease. Parkinsonism Relat Disord. 2017; 36:76-82. DOI: 10.1016/j.parkreldis.2017.01.003. View

11.

Lee E, Hwang I, Park S, Hong S, Hwang B, Cho Y . MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration. Cell Death Differ. 2018; 26(2):213-228. PMC: 6329843. DOI: 10.1038/s41418-018-0124-5. View

12.

De Ceglia R, Ledonne A, Litvin D, Lind B, Carriero G, Latagliata E . Specialized astrocytes mediate glutamatergic gliotransmission in the CNS. Nature. 2023; 622(7981):120-129. PMC: 10550825. DOI: 10.1038/s41586-023-06502-w. View

13.

Hayes M . Parkinson's Disease and Parkinsonism. Am J Med. 2019; 132(7):802-807. DOI: 10.1016/j.amjmed.2019.03.001. View

14.

Jeong S, David S . Glycosylphosphatidylinositol-anchored ceruloplasmin is required for iron efflux from cells in the central nervous system. J Biol Chem. 2003; 278(29):27144-8. DOI: 10.1074/jbc.M301988200. View

15.

Yu X, Xiao Z, Xie J, Xu H . Ferritin Is Secreted from Primary Cultured Astrocyte in Response to Iron Treatment via TRPML1-Mediated Exocytosis. Cells. 2023; 12(21). PMC: 10650167. DOI: 10.3390/cells12212519. View

16.

Jellinger K . Multiple System Atrophy: An Oligodendroglioneural Synucleinopathy1. J Alzheimers Dis. 2017; 62(3):1141-1179. PMC: 5870010. DOI: 10.3233/JAD-170397. View

17.

Dringen R, Bishop G, Koeppe M, Dang T, Robinson S . The pivotal role of astrocytes in the metabolism of iron in the brain. Neurochem Res. 2007; 32(11):1884-90. DOI: 10.1007/s11064-007-9375-0. View

18.

Sun M, Zhu Y, Zhou Z, Jia X, Xu Y, Yang Q . Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson's disease mice: Gut microbiota, glial reaction and TLR4/TNF-α signaling pathway. Brain Behav Immun. 2018; 70:48-60. DOI: 10.1016/j.bbi.2018.02.005. View

19.

Zhang N, Yu X, Song L, Xiao Z, Xie J, Xu H . Ferritin confers protection against iron-mediated neurotoxicity and ferroptosis through iron chelating mechanisms in MPP-induced MES23.5 dopaminergic cells. Free Radic Biol Med. 2022; 193(Pt 2):751-763. DOI: 10.1016/j.freeradbiomed.2022.11.018. View

20.

Zhou H, Su J, Hu X, Zhou C, Li H, Chen Z . Glia-to-Neuron Conversion by CRISPR-CasRx Alleviates Symptoms of Neurological Disease in Mice. Cell. 2020; 181(3):590-603.e16. DOI: 10.1016/j.cell.2020.03.024. View